96 related articles for article (PubMed ID: 28410123)
1. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
Rajawat J; Shukla N; Mishra DP
Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
[TBL] [Abstract][Full Text] [Related]
2. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q; Peng H; Qi X; Wu M; Zhao X
Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
[TBL] [Abstract][Full Text] [Related]
4. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
5. Major clinical research advances in gynecologic cancer in 2019.
Kim M; Suh DH; Lee KH; Eom KY; Lee JY; Lee YY; Hansen HF; Mirza MR; Kim JW
J Gynecol Oncol; 2020 May; 31(3):e48. PubMed ID: 32319232
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours.
Legrand AJ; Choul-Li S; Villeret V; Aumercier M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686260
[TBL] [Abstract][Full Text] [Related]
7. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.
Zhang C; Sheng Y; Sun X; Wang Y
Cancer Metastasis Rev; 2023 Sep; 42(3):891-925. PubMed ID: 37368179
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Pancreatic Cancer.
Brown TJ; Reiss KA
Cancer J; 2021 Nov-Dec 01; 27(6):465-475. PubMed ID: 34904809
[TBL] [Abstract][Full Text] [Related]
9. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.
Kossatz S; Pirovano G; Demétrio De Souza França P; Strome AL; Sunny SP; Zanoni DK; Mauguen A; Carney B; Brand C; Shah V; Ramanajinappa RD; Hedne N; Birur P; Sihag S; Ghossein RA; Gönen M; Strome M; Suresh A; Molena D; Ganly I; Kuriakose MA; Patel SG; Reiner T
Nat Biomed Eng; 2020 Mar; 4(3):272-285. PubMed ID: 32165735
[TBL] [Abstract][Full Text] [Related]
10. Imaging PARP Upregulation with [
Ndlovu H; Lawal I; Mokoala K; Disenyane D; Nkambule N; Bassa S; Mzizi Y; Bida M; Sathekge M
J Nucl Med; 2024 Apr; 65(4):665-666. PubMed ID: 38050115
[No Abstract] [Full Text] [Related]
11. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Liu J; Westin SN
Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
[TBL] [Abstract][Full Text] [Related]
12. Expanding the use of PARP inhibitors in breast cancer.
Tan T
Clin Adv Hematol Oncol; 2023 Sep; 21(9):474-477. PubMed ID: 37647493
[No Abstract] [Full Text] [Related]
13. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
Chen H; Diolaiti ME; O'Leary PC; Rojc A; Krogan NJ; Kim M; Ashworth A
Mol Cancer Ther; 2022 Jul; 21(7):1076-1089. PubMed ID: 35439318
[TBL] [Abstract][Full Text] [Related]
14. Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey.
Cioffi R; Sabetta G; Rabaiotti E; Bergamini A; Bocciolone L; Candotti G; Candiani M; Valabrega G; Mangili G; Pignata S;
Int J Gynecol Cancer; 2021 Oct; 31(10):1363-1368. PubMed ID: 34426526
[TBL] [Abstract][Full Text] [Related]
15. New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
Pommier Y; Thomas A
Clin Cancer Res; 2023 Mar; 29(6):991-993. PubMed ID: 36637483
[TBL] [Abstract][Full Text] [Related]
16. Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
Demidova EV; Ghatalia P; Arora S
Eur Urol; 2022 Feb; 81(2):149-150. PubMed ID: 34753637
[No Abstract] [Full Text] [Related]
17. PARP-targeted Meitner-Auger Electron-emitting Radiopharmaceutical for Radioligand Therapy.
Tan KV
Radiol Imaging Cancer; 2023 Nov; 5(6):e239022. PubMed ID: 37975803
[No Abstract] [Full Text] [Related]
18. Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor.
Sandoval JL; Labidi-Galy SI
Oncogene; 2023 Nov; 42(48):3543-3544. PubMed ID: 37945747
[No Abstract] [Full Text] [Related]
19. Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead.
Willers H; Krause M; Faivre-Finn C; Chalmers AJ
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):265-270. PubMed ID: 34998527
[No Abstract] [Full Text] [Related]
20. Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.
Nuttall Musson E; Miller RE; Mansour MR; Lockley M; Ledermann JA; Payne EM
Leukemia; 2024 Jan; 38(1):215-218. PubMed ID: 37978317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
